Equities

Sentient Brands Holdings Inc

SNBH:PKC

Sentient Brands Holdings Inc

Actions
  • Price (USD)0.042
  • Today's Change-0.026 / -38.24%
  • Shares traded4.10k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 20:51 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sentient Brands Holdings Inc. is a product development and brand management company. The Company focuses on building brands in the luxury and premium market space. It has a direct-to consumer business model focusing on the integration of cannabidiol (CBD), wellness, and beauty for consumers. It develops and supports lifestyle brands through-out-ingredients, packaging, fragrance, and design. It is focused on two market segments: wellness and luxury. Its product line is Oeuvre, which is a CBD luxury skin care line and lifestyle brand. Oeuvre's product offerings include Purifying Exfoliator, Replenishing Facial Oil, Ultra-Nourishing Face Cream, and Revitalizing Eye Cream. Oeuvre products are non-toxic, ungendered products made with zero GMO, retinyl palmitate, petroleum, mineral oil, parabens, sulfates, and synthetic colors. Its products are accessible across digital and retail channels. Its customers include artists, beauty, influencers, bloggers, wellness audiences, and makeup artists.

  • Revenue in USD (TTM)0.00
  • Net income in USD-818.63k
  • Incorporated2020
  • Employees2.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SNBH:PKC since
announced
Transaction
value
American Industrial Group Inc-Food & Beverage PortfolioAnnounced22 Aug 202322 Aug 2023Announced-16.00%--
Data delayed at least 15 minutes, as of Jun 14 2024 20:51 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
cbdMD Inc21.58m-25.65m2.51m52.00--0.6413--0.1164-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
Eloxx Pharmaceuticals Inc0.00-20.48m2.51m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Qrons Inc0.00-763.52k2.53m2.00---------0.0562-0.05620.00-0.10780.00----0.00-18,782.78-1,513.45---------------19.02---------7.61------
Veritas Farms Inc730.65k-6.15m2.62m17.00--12.95--3.59-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
Tharimmune Inc0.00-8.89m2.63m2.00--0.3735-----111.65-111.650.008.970.00----0.00-130.60---173.40--------------0.00-------9.98------
Aridis Pharmaceuticals Inc22.36m-1.14m2.67m37.00------0.1196-0.1845-0.18450.7074-0.26482.40--58.45604,297.30-12.24-120.16---678.29-----5.11-1,559.63--------101.3729.1634.43---34.84--
Aditxt Inc506.45k-41.45m2.70m47.00--0.2717--5.33-109.80-109.800.74885.960.02840.92961.3410,775.53-231.82-192.78-658.00-321.59-27.22---8,149.75-7,208.650.0562-3.420.3915---30.90---18.11------
Sentient Brands Holdings Inc0.00-818.63k2.70m2.00---------0.0145-0.01450.00-0.0360.000.0188--0.00-317.87-220.36------41.81---31,451.190.0354-2.27-----73.68--34.98------
Altamira Therapeutics Ltd118.49k-8.17m2.71m10.00--0.2464--22.88-31.70-26.750.24124.910.015134.0532.3011,849.23-103.88-73.80-6,364.67-123.19-87.90---6,892.99--1.38-4.360.0152------61.02------
Sonoma Pharmaceuticals Inc12.31m-5.08m2.79m9.00--0.3656--0.2267-0.9608-0.96081.950.4890.86252.584.761,367,778.00-35.56-37.52-47.14-51.3539.1740.17-41.23-37.123.11--0.0065--5.10-4.44-1.28--7.54--
Exicure Inc0.00-16.91m2.86m6.00--0.9424-----2.16-2.160.000.35040.00----0.00-96.91-41.52-109.98-55.78-------290.95----0.00---100.00---555.07------
NovaBay Pharmaceuticals Inc14.23m-18.43m2.89m24.00------0.2031-108.80-108.9750.490.17491.412.9111.08593,041.70-108.92-61.51-185.74-83.8954.4759.99-77.22-86.470.7462--0.8629--2.243.32-2.66---15.46--
Petros Pharmaceuticals Inc4.69m-20.46m2.91m21.00--0.2922--0.6197-7.37-7.371.681.550.15420.78582.15223,487.10-29.37-32.43-41.80-68.0569.9162.04-190.50-201.701.46--0.4284---2.83-16.1531.06------
Biostax Corp0.00-1.57m2.93m-----------0.0188-0.01880.00-0.0580.00-------390.77-81.51---------------6.05--------53.32------
Data as of Jun 14 2024. Currency figures normalised to Sentient Brands Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.